A Randomized Phase 2 Study to Evaluate the Efficacy Between Only Radiotherapy Versus CCRT With Temozolomide in Newly Diagnosed Grade III Gliomas Without 1p/19q Codeletion

Trial Profile

A Randomized Phase 2 Study to Evaluate the Efficacy Between Only Radiotherapy Versus CCRT With Temozolomide in Newly Diagnosed Grade III Gliomas Without 1p/19q Codeletion

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Jul 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 10 Apr 2013 New source identified and integrated (Korean Clinical Trials Register; KCT0000700).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top